Boston Scientific Corp. (NYSE: BSX), a leading global medical device manufacturer, is facing an unusual period of stagnation. Known for delivering consistent performance over the years, the company’s stock has treaded water for the last six months. But with the release of its second-quarter earnings scheduled for Wednesday, investors and analysts alike are watching closely for signs of renewed momentum.
Boston Scientific’s stock has historically been a favorite among long-term investors, with a solid track record of innovation in minimally invasive medical technologies. Over the past five years, BSX has significantly outperformed many of its peers in the medtech sector, driven by robust product pipelines and strategic acquisitions.
However, since January 2025, the stock has shown little movement—hovering around the $66 to $70 range. This is despite broader market indices, including the S&P 500 and the Nasdaq Composite, reaching new highs fueled by strong tech and healthcare performance.
Market analysts attribute the recent pause in momentum to a combination of valuation concerns and investor wait-and-see behavior ahead of earnings. “Boston Scientific is not underperforming—it’s consolidating,” said Linda Corrigan, Senior HealthTech Analyst at Fairview Investments. “Investors are waiting for a new catalyst.”
That catalyst could come in the form of Boston Scientific’s Q2 earnings report, which is expected before the market opens on Wednesday.
Wall Street consensus estimates forecast revenue of $3.77 billion for the quarter, up 9.3% year-over-year, and earnings per share (EPS) of $0.61, compared to $0.53 in Q2 2024. The company has beaten EPS estimates in 8 of the last 10 quarters, and analysts are optimistic it will continue that trend.
“The real story will be in the company’s guidance and commentary on growth drivers like the Watchman FLX Pro, Farapulse, and recent expansion in Asia-Pacific markets,” said John Nathan, Equity Research Director at Harding Wealth. “If they deliver a solid beat and raise, BSX could break out of its holding pattern.”
Boston Scientific continues to benefit from its diversified product offerings across cardiology, urology, neuromodulation, and endoscopy. The Watchman heart device and Farapulse pulsed field ablation system remain two of its most closely watched products, with the latter recently gaining traction in Europe and awaiting wider U.S. adoption.
Moreover, the company’s $3.7 billion acquisition of Axonics earlier this year has expanded its footprint in sacral neuromodulation and is expected to be accretive to earnings by late 2025.
In its last earnings call, CEO Mike Mahoney emphasized “strong momentum across our growth platforms” and hinted at further investment in AI-driven diagnostics and robotic-assisted technologies—an area Boston Scientific is expected to ramp up through 2026.
Despite the flat trading pattern, institutional interest in BSX remains strong. According to Bloomberg data, over 68% of the float is held by institutions, including major players like Vanguard, BlackRock, and T. Rowe Price.
The stock currently trades at a forward price-to-earnings (P/E) ratio of 24.5, roughly in line with the sector average. Some analysts believe this leaves room for upside if the company can deliver a strong beat and raise guidance.
Technical analysts note a key resistance level at $71.50. A strong earnings report could push the stock through this ceiling, with bullish targets around $75 to $78 in the near term.
Boston Scientific is at a critical juncture. While its fundamentals remain strong and its long-term outlook is bright, the next few days could determine whether BSX resumes its upward climb or continues to linger in limbo. Wednesday’s earnings report will be a major inflection point for the stock—and possibly for investors seeking medtech exposure in a high-growth, post-pandemic landscape.
